The future of genetics is being redefined with the public launch of Nucleus Genomics’ new AI research arm, Nucleus Labs, and the debut of Origin—a family of nine open-weight artificial intelligence models designed to predict health and longevity from an embryo’s DNA. This marks a pivotal moment in reproductive genetics, as Nucleus becomes the first company in the industry to release AI models with fully transparent weights, enabling open access for researchers, clinicians, and the broader scientific community. Origin, trained and validated on millions of individuals across diverse ancestral backgrounds, delivers unprecedented accuracy in forecasting risks for age-related diseases such as heart disease, cancer, and Alzheimer’s. For couples undergoing in vitro fertilization (IVF), the models offer a powerful new tool: selecting embryos with the lowest genetic risk for major illnesses. According to Nucleus, using just five embryos, families can achieve a greater than 50% reduction in the lifetime risk of conditions like diabetes and several cancers. “This isn’t just about choosing embryos—it’s about shaping healthier futures from the very beginning of life,” said Kian Sadeghi, Founder and CEO of Nucleus Genomics. “We believe the power to improve lifelong health should be accessible, transparent, and collaborative. That’s why we’re open-weighting our models—so the world can build on this science, not just watch it.” In a bold move to promote scientific integrity and accelerate progress, Nucleus has launched the Genetic Optimization Hub, a public platform where researchers and organizations can share models, data, and insights. The Origin family of models is now available on the hub, and Nucleus is actively inviting other institutions to contribute their work, fostering a culture of open innovation in reproductive genomics. The company’s approach challenges the long-standing trend of proprietary secrecy in genetic technology. By making its models freely available, Nucleus aims to ensure that advances in genetic prediction are not limited to a few private labs but are instead developed collectively, ethically, and equitably. The release of Origin is the first in a series of planned open-weight models from Nucleus, with future versions expected to expand capabilities in areas like developmental health, rare disease risk, and personalized longevity planning. The company emphasizes that transparency is not just a technical choice—it’s a moral one. “Technology doesn’t exist in a vacuum,” Sadeghi said. “Its impact depends on how responsibly it’s used. By open-weighting Origin, we’re setting a global standard for safe, inclusive, and effective genetic optimization.” Nucleus Genomics specializes in clinical-grade AI tools for generational health. Its flagship product, Nucleus IVF+, integrates deep genomic analysis into the IVF process, empowering families and clinicians to make data-driven decisions that prioritize long-term well-being. The company continues to expand its mission, inviting partnerships and collaborations through [email protected].